EASTERN COOPERATIVE ONCOLOGY GROUP

描述（由申请人提供）：本申请提交是为了继续宾夕法尼亚大学作为东部肿瘤合作组织的主要机构的角色，在其37年的持续参与之后。总体目标是继续作为该集团的科学和行政资源，将患者纳入ECOG协议，并协调和支持大型附属网络。在后一个角色中，该应用程序将支持临床试验知识的传播，协助临床试验的正确进行，并使这些试验能够为尽可能广泛的癌症患者提供服务。虽然宾夕法尼亚大学在合作小组活动的所有方面，包括应计、行政和科学投入和数据质量方面都有杰出的记录，但今后六年的建议的具体目标是：在我们目前的参与之外，继续加强所有疾病部位和方式的累积，特别是在乳腺癌和肺癌方面。2. 增加医生、护士和数据管理人员对小组活动的参与，包括方案制定。3. 通过艾布拉姆森癌症中心网络吸引新的分支机构，允许在更大的社区中提高临床试验参与的可用性。这个项目与最终治愈癌症的相关性是不言而喻的。合作小组是制药业之外的主要力量，致力于新疗法的最终测试，不仅研究新药开发，还研究非药物治疗，如放射治疗和手术，这些治疗将没有更多的资金。这些合作小组活动，以及宾夕法尼亚大学的具体参与，代表了多模式合作患者护理的最终模式可以执行的主要方式。主要的ECOG拨款详细描述了临床试验导致的非常具体的方式

DESCRIPTION (provided by applicant): This application is being submitted to continue the University of Pennsylvania's role as a main institution in the Eastern Cooperative Oncology Group beyond its 37 years of continuous particpation. The overarching objectives are to continue to serve as a scientific and administrative resource for the Group, to enter patients onto ECOG protocols, and to coordinate and support a large affiliate network. In the latter role, this application will support the diffusion of knowledge of clinical trials, assist in the proper conduct of clinical trials, and make these trials accessible to the broadest possible population of patients with cancer. Although the University of Pennsylvania has had an outstanding track record in all aspects of cooperative group activities, including accrual, administrative and scientific input and data quality, the specific aims of the proposal for the next six years are to: 1. continue to enhance accrual in all disease site and modalities, beyong our current particpation, particularly in breast and lung cancers. 2. increase physician, nurse, and data management participation in Group activities, including protocol development. 3. attract new affilaites through the Abramson Cancer Center network, allowing for enhanced availability for clinical trials participation in the larger community The relevance of this project to the ultimate cure of cancer is self-evident. Cooperative groups are the main force outside of the pharmaceutical industry dedicated to the definitve tesing of new treatments, studying not just new drug development but also non-drug treatment, such as radiation therapy and surgery, for which there would be nooter funding. These cooperative group activities, and the specific involvement of the University of Pennsylvania, represent the chief way in which the ultimate model of multimodal, collaborative patient care can be performed. The main ECOG grant describes in detail the very specific way in which clinical trials have led to RELEVANCE: Malignancies remain an enormous burden for individuals in the United States and for society as a whole. Without public support of clinical trials, both by financial support as well as participation in clinical trials, progress will not be made. If left in private hands, large areas of cancer treatment will go unexplored, denying patients the possibility of progress.